Funding
← Back to your selection

Y Combinator (YC)

Activity from announced rounds

Activity in this selectionBiotech

Y Combinator funds early-stage startups through a three-month accelerator in San Francisco, with four batches a year and a standard $500,000 investment for accepted companies.

The investment consists of $125,000 for 7% of the company and $375,000 on an uncapped SAFE with a most-favoured-nation provision. The second SAFE adds to YC’s ownership when it converts, so the full $500,000 is not exchanged for a fixed 7% stake.

During the batch, founders work with YC partners in individual and group office hours, build toward Demo Day and use the alumni community for feedback, hiring and introductions. Companies can apply before launch; YC also accepts businesses that already have users and revenue.

Sources
Rounds participated in
10
Confirmed lead rounds
0
4 roles undisclosed
New companies
10
First participation on record · 0 follow-on
Funding in participating rounds
$363.3M
8 disclosed · full round size, not this investor’s share

By stage

Seed6
Series A2
Series B1
Series C+1

By primary sector

Biotech7
Healthtech2
Agritech1

By country

United States7
Canada1
Switzerland1
United Kingdom1

Rounds

10 in this selection
Molagri

Molagri develops targeted crop-protection products for growers facing pesticide resistance.

Participant
WonderTx

AI models designed to discover oral medicines for diseases currently treated with injectable drugs.

$125KSeed
Participant
Adaptyv Bio

Adaptyv Bio runs automated laboratory experiments that help protein designers test their sequences and use measured results to improve the next design.

$40MSeries A
Participant
Gamgee

Gamgee develops personalized mRNA vaccines for dogs with cancer, designed from the genetic profile of each dog’s tumor.

$4MSeed
Participant
Rasyn

Rasyn gives chemists a chat interface to run real chemistry software tools on their own hardware.

Participant
Triomics

Building AI infrastructure to turn complex cancer records into structured intelligence

$22MSeries B
Role not disclosed
Blank Bio

Trains RNA foundation models on tumor transcriptomes to improve patient-level prediction in oncology

$7.2MSeed
Role not disclosed
ParcelBio

Develops potent and durable mRNA medicines using the APEXm platform for autoimmune and oncology

$13MSeed
Role not disclosed
Science Corporation

Develops brain-computer interface retinal implants to restore vision in patients with retinal diseases

$230MSeries C
Role not disclosed